Use of novel, non-imidazole inverse agonist radioligands to define histamine H3 receptor pharmacology.
Esbenshade
T A
TA
Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA. Tim.Esbenshade@Abbott.com
Yao
B B
BB
Witte
D G
DG
Carr
T L
TL
Sharma
R
R
Baranowski
J L
JL
Krueger
K M
KM
Miller
T R
TR
Surber
B W
BW
Faghih
R
R
Hancock
A A
AA
D000818:Animals; D001713:Biphenyl Compounds / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D017442:Histamine Agonists / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000737:chemistry; D015394:Molecular Structure; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology*; D011869:Radioligand Assay; D051381:Rats; D018100:Receptors, Histamine H3 / Q000378:metabolism*
C489829:A349821; D001713:Biphenyl Compounds; D017442:Histamine Agonists; D007093:Imidazoles; C475226:N-(2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide; D010879:Piperazines; D018100:Receptors, Histamine H3; C029899:imidazole